ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,302.87
1.07%
Dow Jones
39,844.60
0.72%
US Dollar vs MXN
16.6594
-1.12%
Brent Oil
82.595
0.05%
Bitcoin
65,175.00
5.89%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Adamas Pharmaceuticals Inc (ADMS)

  7. Adamas Pharmaceuticals Inc (ADMS) Noticias

ADMS

Adamas Pharmaceuticals (ADMS)

Adamas Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ADMS
FechaHoraFuenteTítuloSímboloCompañía
15/02/202205:35Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ADMSAdamas Pharmaceuticals Inc
02/12/202105:15Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:ADMSAdamas Pharmaceuticals Inc
24/11/202115:12Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ADMSAdamas Pharmaceuticals Inc
24/11/202110:54Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:ADMSAdamas Pharmaceuticals Inc
24/11/202108:28Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:ADMSAdamas Pharmaceuticals Inc
24/11/202108:18Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ADMSAdamas Pharmaceuticals Inc
24/11/202108:17Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:ADMSAdamas Pharmaceuticals Inc
24/11/202108:12GlobeNewswire Inc.Supernus Pharmaceuticals Completes Acquisition of Adamas PharmaceuticalsNASDAQ:ADMSAdamas Pharmaceuticals Inc
23/11/202107:22Edgar (US Regulatory)Amended Tender Offer Statement by Third Party (sc To-t/a)NASDAQ:ADMSAdamas Pharmaceuticals Inc
23/11/202107:00GlobeNewswire Inc.Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender OfferNASDAQ:ADMSAdamas Pharmaceuticals Inc
10/11/202115:03Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ADMSAdamas Pharmaceuticals Inc
01/11/202115:55Edgar (US Regulatory)Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)NASDAQ:ADMSAdamas Pharmaceuticals Inc
25/10/202110:26Edgar (US Regulatory)Statement of Ownership: Solicitation (sc 14d9)NASDAQ:ADMSAdamas Pharmaceuticals Inc
25/10/202109:22Edgar (US Regulatory)Tender Offer Statement by Third Party (sc To-t)NASDAQ:ADMSAdamas Pharmaceuticals Inc
19/10/202115:27Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:ADMSAdamas Pharmaceuticals Inc
12/10/202106:56Edgar (US Regulatory)Written Communication Relating to an Issuer or Third Party (sc To-c)NASDAQ:ADMSAdamas Pharmaceuticals Inc
11/10/202105:30GlobeNewswire Inc.Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product PortfolioNASDAQ:ADMSAdamas Pharmaceuticals Inc
08/10/202115:15Business WireAdamas Announces New Employment Inducement GrantsNASDAQ:ADMSAdamas Pharmaceuticals Inc
01/10/202108:15Business WireAdamas Named 2021 Finalist in the New Therapeutics Category of the UCSF Health AwardsNASDAQ:ADMSAdamas Pharmaceuticals Inc
16/09/202108:15Business WireAdamas Announces GOCOVRI Presentations at the Upcoming International Parkinson and Movement Disorder Society’s (MDS) CongressNASDAQ:ADMSAdamas Pharmaceuticals Inc
30/08/202115:11Business WireAdamas to Present at Upcoming September Investor ConferencesNASDAQ:ADMSAdamas Pharmaceuticals Inc
13/08/202115:16Business WireAdamas Announces New Employment Inducement GrantNASDAQ:ADMSAdamas Pharmaceuticals Inc
09/08/202115:01Business WireAdamas Reports Second Quarter 2021 Financial ResultsNASDAQ:ADMSAdamas Pharmaceuticals Inc
02/08/202115:02Business WireAdamas to Announce Second Quarter Financial Results and Host Conference Call on August 9, 2021NASDAQ:ADMSAdamas Pharmaceuticals Inc
22/07/202108:15Business WireAdamas Announces Issuance of New Patents for GOCOVRI and ADS-4101NASDAQ:ADMSAdamas Pharmaceuticals Inc
08/07/202115:02Business WireAdamas to Present at Upcoming William Blair Biotech Focus ConferenceNASDAQ:ADMSAdamas Pharmaceuticals Inc
23/06/202115:42Business WireAdamas to Present at Upcoming SVB Leerink CNS ForumNASDAQ:ADMSAdamas Pharmaceuticals Inc
10/06/202108:15Business WireNew Data Analysis Supports GOCOVRI as an Important Treatment for Motor Complications for People With Parkinson’s DiseaseNASDAQ:ADMSAdamas Pharmaceuticals Inc
27/05/202115:11Business WireAdamas to Present at Upcoming June ConferencesNASDAQ:ADMSAdamas Pharmaceuticals Inc
10/05/202115:02Business WireAdamas Reports First Quarter 2021 Financial ResultsNASDAQ:ADMSAdamas Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ADMS

Su Consulta Reciente

NYSE
BAC
Bank of America
COIN
BTCUSD
Bitcoin
USOTC
RHHBY
Roche (QX)
NYSE
CVX
Chevron
USOTC
BASFY
BASF (QX)
NYSE
DIS
Walt Disney
NASDAQ
MSFT
Microsoft
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
MRK
Merck
NYSE
NKE
Nike
NYSE
VZ
Verizon Communications
CCOM
SILVER
SILVER
NASDAQ
TSLA
Tesla
COIN
ETHUSD
Ethereum
FX
EURMXN
Euro vs MXN
USI
USTECH100
US Tech 100
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados